Abstract |
To assess the efficacy and safety of verapamil in variant angina pectoris, we entered 16 patients in a double-blind, randomized trial of nine months, duration. During treatment with verapamil, the frequency of angina fell substantially (12.6 +/- 25.9 chest pains per week with placebo, 1.7 +/- 2.8 pains per week with verapamil, mean +/- S.D.; P less than 0.01), as did the use of nitroglycerin tablets (14.4 +/- 34.4 tablets per week with placebo, 2.1 +/- 3.3 tablets per week with verapamil; P less than 0.05). The number of hospitalizations for clinical instability was significantly lower with verapamil (P less than 0.01). The number of episodes of transient ST-segment deviation during treatment with verapamil was reduced (33.1 +/- 39.3 ST-segment deviations per week with placebo, 7.7 +/- 11.7 deviations per week with verapamil; P less than 0.01). Verapamil caused no side effects forcing a reduction in dosage or a discontinuation. We conclude that verapamil is safe and effective in the therapy of variant angina pectoris.
|
Authors | S M Johnson, D R Mauritson, J T Willerson, L D Hillis |
Journal | The New England journal of medicine
(N Engl J Med)
Vol. 304
Issue 15
Pg. 862-6
(Apr 09 1981)
ISSN: 0028-4793 [Print] United States |
PMID | 6782480
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
|
Topics |
- Adult
- Angina Pectoris
(drug therapy)
- Angina Pectoris, Variant
(diagnosis, drug therapy)
- Clinical Trials as Topic
- Double-Blind Method
- Electrocardiography
- Female
- Humans
- Male
- Middle Aged
- Nitroglycerin
(administration & dosage)
- Random Allocation
- Time Factors
- Verapamil
(administration & dosage, adverse effects, therapeutic use)
|